Jason Haas - Oct 12, 2021 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Financial Officer
Signature
/s/ Jason Haas
Stock symbol
SYRS
Transactions as of
Oct 12, 2021
Transactions value $
$0
Form type
4
Date filed
10/13/2021, 04:06 PM
Next filing
Feb 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +750K $0.00 750K Oct 12, 2021 Common Stock 750K $4.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to one quarter (1/4th) of the shares on October 12, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.